Reply to “Do not de-escalate oncology care in oropharyngeal cancer routinely”
Corresponding Author
Taru Ilmarinen MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Correspondence
Taru Ilmarinen, Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland.
Email: [email protected]
Search for more papers by this authorHarri T. Keski-Säntti MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorMari L. Markkanen-Leppänen MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorAaro Haapaniemi MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorLaura Tapiovaara MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorTimo Atula MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorLeif Bäck MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorCorresponding Author
Taru Ilmarinen MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Correspondence
Taru Ilmarinen, Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland.
Email: [email protected]
Search for more papers by this authorHarri T. Keski-Säntti MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorMari L. Markkanen-Leppänen MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorAaro Haapaniemi MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorLaura Tapiovaara MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorTimo Atula MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorLeif Bäck MD, PhD
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this author
REFERENCES
- 1Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014; 32: 3365-3373.
- 2Frakes JM, Naghavi AO, Demetriou SK, et al. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer. 2016; 122: 634-641.
- 3Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
- 4O'Sullivan B, Huang SH, Perez-Ordonez B, et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol. 2012; 103: 49-56.
- 5Huang SH, Perez-Ordonez B, Weinreb I, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013; 49: 79-85.
- 6Trosman SJ, Koyfman SA, Ward MC, et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg. 2015; 141: 457-462.
- 7Gronhoj C, Jakobsen KK, Jensen DH, et al. Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma: a population-based study. Oral Oncol. 2018; 83: 127-133.
- 8Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019; 7: 184-019-0662-5.
- 9Masroor F, Corpman D, Carpenter DM, et al. Association of NCCN-recommended posttreatment surveillance with outcomes in patients with HPV-associated oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2019; doi: 10.1001/jamaoto.2019.1934.
- 10Mueller SA, Riggauer J, Elicin O, Blaser D, Trelle S, Giger R. Patients' preferences concerning follow-up after curative head and neck cancer treatment: a cross-sectional pilot study. Head Neck. 2019; 41: 2174-2181.
